|
|
|
|
| LEADER |
01998nam a2200265 u 4500 |
| 001 |
EB002191729 |
| 003 |
EBX01000000000000001329194 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.)
|h Elektronische Ressource
|b indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
|
| 246 |
3 |
1 |
|a CADTH common drug review Pharmacoeconomic review report for Belimumab (Benlysta)
|
| 246 |
3 |
1 |
|a Belimumab (Benlysta) (GlaxoSmithKline inc.)
|
| 250 |
|
|
|a Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2020, June 2020
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK564629
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with active, autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly formulation. The submitted price is $421.79 per 200 mg. At the recommended dosage of 200 mg weekly, the average annual cost is $21,933 per patient. Belimumab was previously reviewed by CADTH for the IV infusion. CADTH Canadian Drug Expert Committee (CDEC) recommended belimumab IV not be reimbursed because its clinical benefit was uncertain and its cost-effectiveness could not be adequately assessed
|